Bristol Myers Squibb Company (NYSE:BMY) Stock Holdings Trimmed by Bartlett & CO. Wealth Management LLC

Bartlett & CO. Wealth Management LLC lessened its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 4.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 159,172 shares of the biopharmaceutical company's stock after selling 7,531 shares during the period. Bartlett & CO. Wealth Management LLC's holdings in Bristol Myers Squibb were worth $9,708,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Polar Asset Management Partners Inc. acquired a new position in Bristol Myers Squibb in the fourth quarter worth $16,651,000. Avaii Wealth Management LLC boosted its holdings in shares of Bristol Myers Squibb by 590.9% in the 1st quarter. Avaii Wealth Management LLC now owns 78,597 shares of the biopharmaceutical company's stock valued at $4,794,000 after buying an additional 67,221 shares during the period. Assenagon Asset Management S.A. raised its stake in Bristol Myers Squibb by 1.4% during the first quarter. Assenagon Asset Management S.A. now owns 65,038 shares of the biopharmaceutical company's stock worth $3,967,000 after acquiring an additional 869 shares during the period. Shorepoint Capital Partners LLC lifted its holdings in Bristol Myers Squibb by 2.2% in the fourth quarter. Shorepoint Capital Partners LLC now owns 58,426 shares of the biopharmaceutical company's stock worth $3,305,000 after acquiring an additional 1,248 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in Bristol Myers Squibb by 17.0% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 550,613 shares of the biopharmaceutical company's stock valued at $33,582,000 after acquiring an additional 80,087 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on BMY. Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 target price on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. The Goldman Sachs Group restated a "neutral" rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Piper Sandler began coverage on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective on the stock. Finally, Jefferies Financial Group reduced their target price on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of "Hold" and a consensus price target of $58.00.

Insider Buying and Selling

In related news, EVP Samit Hirawat purchased 4,250 shares of the stock in a transaction dated Friday, April 25th. The shares were acquired at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.09% of the stock is currently owned by insiders.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY opened at $46.68 on Friday. Bristol Myers Squibb Company has a 1 year low of $39.35 and a 1 year high of $63.33. The firm has a market cap of $95.01 billion, a P/E ratio of 17.48, a PEG ratio of 1.38 and a beta of 0.38. The stock has a fifty day moving average price of $47.96 and a two-hundred day moving average price of $54.02. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The business had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter last year, the business posted ($4.40) earnings per share. The company's quarterly revenue was down 5.6% on a year-over-year basis. Research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.31%. The ex-dividend date is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is presently 92.88%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.